Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: Results from the phase III, placebo-controlled QUAZAR AML-001 trial

Gail J. Roboz; Hartmut Döhner; Christopher Pocock; Hervé Dombret; Farhad Ravandi; Jun Ho Jang; Dominik Selleslag; Jiří Mayer; Uwe M. Martens; Jane Liesveld; Teresa Bernal; Ming Chung Wang; Peiwen Yu; Ling Shi; Shien Guo; Ignazia La Torre; Barry Skikne; Qian Dong; Julia Braverman; Salem Abi Nehme; C. L. Beach; Andrew H. Wei

doi:10.3324/haematol.2021.279174

Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: Results from the phase III, placebo-controlled QUAZAR AML-001 trial

Gail J. Roboz, Hartmut Döhner, Christopher Pocock, Hervé Dombret, Farhad Ravandi, Jun Ho Jang, Dominik Selleslag, Jiří Mayer, Uwe M. Martens, Jane Liesveld, Teresa Bernal, Ming Chung Wang, Peiwen Yu, Ling Shi, Shien Guo, Ignazia La Torre, Barry Skikne, Qian Dong, Julia Braverman, Salem Abi NehmeC. L. Beach, Andrew H. Wei

Leukemia

Research output: Contribution to journal › Letter › peer-review

7 Scopus citations

Original language	English (US)
Pages (from-to)	3240-3244
Number of pages	5
Journal	Haematologica
Volume	106
Issue number	12
DOIs	https://doi.org/10.3324/haematol.2021.279174
State	Published - Dec 2021

ASJC Scopus subject areas

Hematology

Access to Document

10.3324/haematol.2021.279174

Cite this

Roboz, G. J., Döhner, H., Pocock, C., Dombret, H., Ravandi, F., Jang, J. H., Selleslag, D., Mayer, J., Martens, U. M., Liesveld, J., Bernal, T., Wang, M. C., Yu, P., Shi, L., Guo, S., Torre, I. L., Skikne, B., Dong, Q., Braverman, J., ... Wei, A. H. (2021). Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: Results from the phase III, placebo-controlled QUAZAR AML-001 trial. Haematologica, 106(12), 3240-3244. https://doi.org/10.3324/haematol.2021.279174

Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: Results from the phase III, placebo-controlled QUAZAR AML-001 trial. / Roboz, Gail J.; Döhner, Hartmut; Pocock, Christopher et al.
In: Haematologica, Vol. 106, No. 12, 12.2021, p. 3240-3244.

Research output: Contribution to journal › Letter › peer-review

Roboz, GJ, Döhner, H, Pocock, C, Dombret, H, Ravandi, F, Jang, JH, Selleslag, D, Mayer, J, Martens, UM, Liesveld, J, Bernal, T, Wang, MC, Yu, P, Shi, L, Guo, S, Torre, IL, Skikne, B, Dong, Q, Braverman, J, Nehme, SA, Beach, CL & Wei, AH 2021, 'Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: Results from the phase III, placebo-controlled QUAZAR AML-001 trial', Haematologica, vol. 106, no. 12, pp. 3240-3244. https://doi.org/10.3324/haematol.2021.279174

@article{35471b3092464e63b4a0fc42d6213b46,

title = "Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: Results from the phase III, placebo-controlled QUAZAR AML-001 trial",

author = "Roboz, {Gail J.} and Hartmut D{\"o}hner and Christopher Pocock and Herv{\'e} Dombret and Farhad Ravandi and Jang, {Jun Ho} and Dominik Selleslag and Ji{\v r}{\'i} Mayer and Martens, {Uwe M.} and Jane Liesveld and Teresa Bernal and Wang, {Ming Chung} and Peiwen Yu and Ling Shi and Shien Guo and Torre, {Ignazia La} and Barry Skikne and Qian Dong and Julia Braverman and Nehme, {Salem Abi} and Beach, {C. L.} and Wei, {Andrew H.}",

note = "Funding Information: Contributions: the sponsors collected and analyzed data in conjunction with all authors. The lead author wrote the initial draft of the manuscript. All authors revised the manuscript and reviewed and approved the final version for submission. Acknowledgments: additional support on an early draft of the manuscript was provided by Sheila Truten and Brian Kaiser from Medical Communication Company, Inc. (Wynnewood, PA, USA), funded by Bristol Myers Squibb and in accordance with Good Publication Practice guidelines Funding: this study was sponsored and funded by Celgene, a Bristol-Myers Squibb Company. Data sharing statement: BMS policy on data sharing may be found at https://www.bms.com/researchers-and-partners/independent-research/data-sharing-request-process.html Funding Information: Disclosures: GJR reports consultancy or advisory board or data and safety monitoring committee of AbbVie, Actinium, Agios, Amphivena, Amgen, Argenx, Array Biopharma, Astex, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, Celltrion, Daiichi Sankyo, Eisai, Epizyme, GlaxoSmithKline, Helsinn, Janssen, Jasper Therapeutics, Jazz, Mesoblast, MEI Pharma (IDMC Chair), Novartis, Orsenix, Otsuka, Pfizer, Roche/Genentech, Sandoz, Takeda (IRC Chair), Trovagene; and research support from Cellectis. HD reports personal fees from Abbvie, Agios, Astellas, Astex Pharmaceuticals, Helsinn, Janssen, Oxford Biomedicals, and Roche; grants and personal fees from Amgen, Celgene, Jazz Pharmaceuticals, and Novartis; and grants from AROG Pharmaceuticals, Bristol Myers Squibb, Pfizer, and Sunesis. HD reports grants and personal fees from Celgene, Amgen, Incyte, Novartis, Jazz Pharmaceuticals, Daiichi Sankyo, Servier, and Astellas; and personal fees from Pfizer, Cellectis, Menarini, Otsuka, AbbVie, Janssen, Shire-Baxalta, Celyad, Agios, and Immunogen. FR reports honoraria and consulting fees from Bristol Myers Squibb and Celgene; and research funding from Bristol Myers Squibb. DS reports honoraria from Novartis, Celgene, Amgen, Janssen-Cilag, AbbVie, Alexion, GSK, MSD, Pfizer, Sanofi , Takeda, Incyte, and Teva; consultancy for Novartis, Celgene, Amgen, Janssen-Cilag, AbbVie, Alexion, GSK, MSD, Pfizer, Sanofi, Takeda, Incyte, and Teva; and speakers{\textquoteright} bureau participation for Novartis, Celgene, Amgen, MSD, Takeda, and Teva. JM reports research funding from Celgene. UMM reports consultancy for Bristol Myers Squibb, Merck, Amgen, Roche, and Celgene; and travel accommodations/expenses from Bristol Myers Squibb, Amgen, Pierre-Fabre, and Celgene. JL reports participation in DSMB for Onconova. PY, LS, and SG are employed by Evidera. BS is employed by Bristol Myers Squibb. ILT, QD, JB, SAN, and CLB are employed at and have equity ownership in Bristol Myers Squibb. AHW reports study-related fees and personal fees from Celgene; royalties from Walter and Eliza Hall Institute of Medical Research; grants from the Medical Research Future Fund; grants and personal fees from Servier, AbbVie, Novartis, Celgene, Astra Zeneca, and Janssen; and personal fees from Astellas, Pfizer, Macrogenics, and Amgen. CP, JHJ, TB, and MCW report no conflicts of interest.",

year = "2021",

month = dec,

doi = "10.3324/haematol.2021.279174",

language = "English (US)",

volume = "106",

pages = "3240--3244",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "12",

}

TY - JOUR

T1 - Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission

T2 - Results from the phase III, placebo-controlled QUAZAR AML-001 trial

AU - Roboz, Gail J.

AU - Döhner, Hartmut

AU - Pocock, Christopher

AU - Dombret, Hervé

AU - Ravandi, Farhad

AU - Jang, Jun Ho

AU - Selleslag, Dominik

AU - Mayer, Jiří

AU - Martens, Uwe M.

AU - Liesveld, Jane

AU - Bernal, Teresa

AU - Wang, Ming Chung

AU - Yu, Peiwen

AU - Shi, Ling

AU - Guo, Shien

AU - Torre, Ignazia La

AU - Skikne, Barry

AU - Dong, Qian

AU - Braverman, Julia

AU - Nehme, Salem Abi

AU - Beach, C. L.

AU - Wei, Andrew H.

N1 - Funding Information: Contributions: the sponsors collected and analyzed data in conjunction with all authors. The lead author wrote the initial draft of the manuscript. All authors revised the manuscript and reviewed and approved the final version for submission. Acknowledgments: additional support on an early draft of the manuscript was provided by Sheila Truten and Brian Kaiser from Medical Communication Company, Inc. (Wynnewood, PA, USA), funded by Bristol Myers Squibb and in accordance with Good Publication Practice guidelines Funding: this study was sponsored and funded by Celgene, a Bristol-Myers Squibb Company. Data sharing statement: BMS policy on data sharing may be found at https://www.bms.com/researchers-and-partners/independent-research/data-sharing-request-process.html Funding Information: Disclosures: GJR reports consultancy or advisory board or data and safety monitoring committee of AbbVie, Actinium, Agios, Amphivena, Amgen, Argenx, Array Biopharma, Astex, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, Celltrion, Daiichi Sankyo, Eisai, Epizyme, GlaxoSmithKline, Helsinn, Janssen, Jasper Therapeutics, Jazz, Mesoblast, MEI Pharma (IDMC Chair), Novartis, Orsenix, Otsuka, Pfizer, Roche/Genentech, Sandoz, Takeda (IRC Chair), Trovagene; and research support from Cellectis. HD reports personal fees from Abbvie, Agios, Astellas, Astex Pharmaceuticals, Helsinn, Janssen, Oxford Biomedicals, and Roche; grants and personal fees from Amgen, Celgene, Jazz Pharmaceuticals, and Novartis; and grants from AROG Pharmaceuticals, Bristol Myers Squibb, Pfizer, and Sunesis. HD reports grants and personal fees from Celgene, Amgen, Incyte, Novartis, Jazz Pharmaceuticals, Daiichi Sankyo, Servier, and Astellas; and personal fees from Pfizer, Cellectis, Menarini, Otsuka, AbbVie, Janssen, Shire-Baxalta, Celyad, Agios, and Immunogen. FR reports honoraria and consulting fees from Bristol Myers Squibb and Celgene; and research funding from Bristol Myers Squibb. DS reports honoraria from Novartis, Celgene, Amgen, Janssen-Cilag, AbbVie, Alexion, GSK, MSD, Pfizer, Sanofi , Takeda, Incyte, and Teva; consultancy for Novartis, Celgene, Amgen, Janssen-Cilag, AbbVie, Alexion, GSK, MSD, Pfizer, Sanofi, Takeda, Incyte, and Teva; and speakers’ bureau participation for Novartis, Celgene, Amgen, MSD, Takeda, and Teva. JM reports research funding from Celgene. UMM reports consultancy for Bristol Myers Squibb, Merck, Amgen, Roche, and Celgene; and travel accommodations/expenses from Bristol Myers Squibb, Amgen, Pierre-Fabre, and Celgene. JL reports participation in DSMB for Onconova. PY, LS, and SG are employed by Evidera. BS is employed by Bristol Myers Squibb. ILT, QD, JB, SAN, and CLB are employed at and have equity ownership in Bristol Myers Squibb. AHW reports study-related fees and personal fees from Celgene; royalties from Walter and Eliza Hall Institute of Medical Research; grants from the Medical Research Future Fund; grants and personal fees from Servier, AbbVie, Novartis, Celgene, Astra Zeneca, and Janssen; and personal fees from Astellas, Pfizer, Macrogenics, and Amgen. CP, JHJ, TB, and MCW report no conflicts of interest.

PY - 2021/12

Y1 - 2021/12

UR - http://www.scopus.com/inward/record.url?scp=85120738327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85120738327&partnerID=8YFLogxK

U2 - 10.3324/haematol.2021.279174

DO - 10.3324/haematol.2021.279174

M3 - Letter

C2 - 34551506

AN - SCOPUS:85120738327

SN - 0390-6078

VL - 106

SP - 3240

EP - 3244

JO - Haematologica

JF - Haematologica

IS - 12

ER -

Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: Results from the phase III, placebo-controlled QUAZAR AML-001 trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this